Skip to main content
Erschienen in: Rheumatology International 11/2011

01.11.2011 | Original Article

Incidence of malignancy in Japanese patients with rheumatoid arthritis

verfasst von: Toru Yamada, Ayako Nakajima, Eisuke Inoue, Eiichi Tanaka, Atsuo Taniguchi, Shigeki Momohara, Hisashi Yamanaka

Erschienen in: Rheumatology International | Ausgabe 11/2011

Einloggen, um Zugang zu erhalten

Abstract

To determine the incidence of malignancy and site-specific malignancies in Japanese patients with rheumatoid arthritis (RA). In a prospective large observational cohort study named IORRA, 7,566 patients with RA were enrolled from April 2001 to April 2005 and were followed up to October 2005. Occurrence of malignancy was originally collected by patient reports of IORRA survey biannually from April 2001 to October 2005, and was confirmed by medical records. Standardized incidence rate (SIR) of the observed-to-expected cancer incidence and 95% confidence intervals (95% CI) were then calculated. Factors obtained at first enrollment in IORRA were assessed for association with risk of malignancy using the Cox proportional hazards model. A total of 177 malignancies in 173 patients (58 in men, 115 in women) were identified during the observation period of 25,567 person-years. The age- and sex-standardized incidence rate of malignancy was 437.1 (men, 706.8; women, 366.1) per 100,000 person-years. The SIR of malignancy was slightly excess (SIR 1.18, [95% CI 1.02–1.37]) in all patients, but 1.29 (95% CI 0.99–1.67) in men, and 1.13 (95% CI 0.94–1.36) in women. A significant excess of lymphoma (SIR 6.07, [95% CI 3.71–9.37]) and lung cancer (SIR 2.29, [95% CI 1.57–3.21]), whereas decreased incidence of colorectal cancer (SIR 0.49, [95% CI 0.26–0.83]), were found. Male gender and older age were identified as risk factors for malignancy. A slight excess in the incidence of overall malignancy and highly excess of lymphoma in Japanese RA patients was demonstrated.
Literatur
1.
Zurück zum Zitat Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL (2002) Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 29:62–67PubMed Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL (2002) Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol 29:62–67PubMed
2.
Zurück zum Zitat Young A, Koduri G, Batley M et al (2007) Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46:350–357CrossRef Young A, Koduri G, Batley M et al (2007) Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 46:350–357CrossRef
3.
Zurück zum Zitat Kuroda T, Tanabe N, Harada T et al (2006) Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 25:498–505PubMedCrossRef Kuroda T, Tanabe N, Harada T et al (2006) Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 25:498–505PubMedCrossRef
4.
Zurück zum Zitat Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:722–732PubMedCrossRef Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2005) Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52:722–732PubMedCrossRef
5.
Zurück zum Zitat Wallberg-Jonsson S, Ohman ML, Dahlqvist SR (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol 24:445–451PubMed Wallberg-Jonsson S, Ohman ML, Dahlqvist SR (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in northern Sweden. J Rheumatol 24:445–451PubMed
6.
Zurück zum Zitat Hoshida Y, Xu JX, Fujita S et al (2007) Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34:322–331PubMed Hoshida Y, Xu JX, Fujita S et al (2007) Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34:322–331PubMed
7.
Zurück zum Zitat Smitten AL, Choi HK, Hochberg MC et al (2008) The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35:387–393PubMed Smitten AL, Choi HK, Hochberg MC et al (2008) The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35:387–393PubMed
8.
Zurück zum Zitat Smitten AL, Simon TA, Hochberg MC, Suissa S (2008) A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10:R45PubMedCrossRef Smitten AL, Simon TA, Hochberg MC, Suissa S (2008) A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10:R45PubMedCrossRef
9.
Zurück zum Zitat Abasolo L, Judez E, Descalzo MA, Gonzalez-Alvaro I, Jover JA, Carmona L (2008) Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a south European population. Semin Arthritis Rheum 37:388–397PubMedCrossRef Abasolo L, Judez E, Descalzo MA, Gonzalez-Alvaro I, Jover JA, Carmona L (2008) Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a south European population. Semin Arthritis Rheum 37:388–397PubMedCrossRef
10.
Zurück zum Zitat Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, Ollier WE, Martin J, Gonzalez-Gay MA (2007) Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum 37:31–38PubMedCrossRef Llorca J, Lopez-Diaz MJ, Gonzalez-Juanatey C, Ollier WE, Martin J, Gonzalez-Gay MA (2007) Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain. Semin Arthritis Rheum 37:31–38PubMedCrossRef
11.
Zurück zum Zitat Franklin J, Lunt M, Bunn D, Symmons D, Silman A (2007) Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community-based prospective study. Arthritis Rheum 56:790–798PubMedCrossRef Franklin J, Lunt M, Bunn D, Symmons D, Silman A (2007) Influence of inflammatory polyarthritis on cancer incidence and survival: results from a community-based prospective study. Arthritis Rheum 56:790–798PubMedCrossRef
12.
Zurück zum Zitat Geborek P, Bladstrom A, Turesson C et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699–703PubMedCrossRef Geborek P, Bladstrom A, Turesson C et al (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64:699–703PubMedCrossRef
13.
Zurück zum Zitat Prior P, Symmons DP, Hawkins CF, Scott DL, Brown R (1984) Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 43:128–131PubMedCrossRef Prior P, Symmons DP, Hawkins CF, Scott DL, Brown R (1984) Cancer morbidity in rheumatoid arthritis. Ann Rheum Dis 43:128–131PubMedCrossRef
14.
Zurück zum Zitat Cibere J, Sibley J, Haga M (1997) Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 40:1580–1586PubMedCrossRef Cibere J, Sibley J, Haga M (1997) Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 40:1580–1586PubMedCrossRef
15.
Zurück zum Zitat Beauparlant P, Papp K, Haraoui B (1999) The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:148–158PubMedCrossRef Beauparlant P, Papp K, Haraoui B (1999) The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29:148–158PubMedCrossRef
16.
Zurück zum Zitat Askling J, Fored CM, Baecklund E et al (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64:1414–1420PubMedCrossRef Askling J, Fored CM, Baecklund E et al (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64:1414–1420PubMedCrossRef
17.
Zurück zum Zitat Setoguchi S, Solomon DH, Weinblatt ME et al (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54:2757–2764PubMedCrossRef Setoguchi S, Solomon DH, Weinblatt ME et al (2006) Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54:2757–2764PubMedCrossRef
18.
Zurück zum Zitat Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A:1753–1757PubMedCrossRef Mellemkjaer L, Linet MS, Gridley G, Frisch M, Moller H, Olsen JH (1996) Rheumatoid arthritis and cancer risk. Eur J Cancer 32A:1753–1757PubMedCrossRef
19.
Zurück zum Zitat Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497–502PubMedCrossRef Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88:497–502PubMedCrossRef
20.
Zurück zum Zitat Georgescu L, Quinn GC, Schwartzman S, Paget SA (1997) Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 26:794–804PubMedCrossRef Georgescu L, Quinn GC, Schwartzman S, Paget SA (1997) Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 26:794–804PubMedCrossRef
21.
Zurück zum Zitat Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701PubMedCrossRef Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701PubMedCrossRef
22.
Zurück zum Zitat Kojima M, Itoh H, Hirabayashi K et al (2006) Methtrexate-associated lymphoproliferative disorders. A clinicopathological study of 13 Japanese cases. Pathol Res Pract 202:679–685PubMedCrossRef Kojima M, Itoh H, Hirabayashi K et al (2006) Methtrexate-associated lymphoproliferative disorders. A clinicopathological study of 13 Japanese cases. Pathol Res Pract 202:679–685PubMedCrossRef
23.
Zurück zum Zitat Shinomiya F, Mima N, Nanba K et al (2008) Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period. Mod Rheumatol 18:165–169PubMedCrossRef Shinomiya F, Mima N, Nanba K et al (2008) Life expectancies of Japanese patients with rheumatoid arthritis: a review of deaths over a 20-year period. Mod Rheumatol 18:165–169PubMedCrossRef
24.
Zurück zum Zitat Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, Shidara K, Hara M, Momohara S, Taniguchi A, Kamatani N, Yamanaka H (2010) Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol (in press) Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, Shidara K, Hara M, Momohara S, Taniguchi A, Kamatani N, Yamanaka H (2010) Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol (in press)
25.
Zurück zum Zitat Yamanaka H, Inoue E, Singh G et al (2007) Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol 17:283–289PubMedCrossRef Yamanaka H, Inoue E, Singh G et al (2007) Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol 17:283–289PubMedCrossRef
26.
Zurück zum Zitat Yamada T, Nakajima A, Inoue E et al (2006) Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 65:1661–1663PubMedCrossRef Yamada T, Nakajima A, Inoue E et al (2006) Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 65:1661–1663PubMedCrossRef
27.
Zurück zum Zitat Nakajima A, Kamitsuji S, Saito A et al (2006) Disability and patient’s appraisal of general health contribute to depressed mood in rheumatoid arthritis in a large clinical study in Japan. Mod Rheumatol 16:151–157PubMedCrossRef Nakajima A, Kamitsuji S, Saito A et al (2006) Disability and patient’s appraisal of general health contribute to depressed mood in rheumatoid arthritis in a large clinical study in Japan. Mod Rheumatol 16:151–157PubMedCrossRef
28.
Zurück zum Zitat Matsuda Y, Singh G, Yamanaka H et al (2003) Validation of a Japanese version of the Stanford health assessment questionnaire in 3, 763 patients with rheumatoid arthritis. Arthritis Rheum 49:784–788PubMedCrossRef Matsuda Y, Singh G, Yamanaka H et al (2003) Validation of a Japanese version of the Stanford health assessment questionnaire in 3, 763 patients with rheumatoid arthritis. Arthritis Rheum 49:784–788PubMedCrossRef
29.
Zurück zum Zitat Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T (2008) Cancer incidence and incidence rates in Japan in 2002: Based on data from 11 population-based cancer registries. Jpn J Clin Oncol 38:641–648PubMedCrossRef Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T (2008) Cancer incidence and incidence rates in Japan in 2002: Based on data from 11 population-based cancer registries. Jpn J Clin Oncol 38:641–648PubMedCrossRef
30.
Zurück zum Zitat Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS (1992) Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 19:1462–1465PubMed Kingsmore SF, Hall BD, Allen NB, Rice JR, Caldwell DS (1992) Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review. J Rheumatol 19:1462–1465PubMed
31.
Zurück zum Zitat Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW (1996) Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum 39:325–329PubMedCrossRef Bachman TR, Sawitzke AD, Perkins SL, Ward JH, Cannon GW (1996) Methotrexate-associated lymphoma in patients with rheumatoid arthritis: report of two cases. Arthritis Rheum 39:325–329PubMedCrossRef
32.
Zurück zum Zitat Hoshida Y, Tomita Y, Zhiming D et al (2004) Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer 108:443–449PubMedCrossRef Hoshida Y, Tomita Y, Zhiming D et al (2004) Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer 108:443–449PubMedCrossRef
33.
Zurück zum Zitat Rizzi R, Curci P, Delia M et al (2009) Spontaneous remission of “Methotrexate-associated lymphoproliferative disorders” After discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 26:1–9PubMedCrossRef Rizzi R, Curci P, Delia M et al (2009) Spontaneous remission of “Methotrexate-associated lymphoproliferative disorders” After discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol 26:1–9PubMedCrossRef
34.
Zurück zum Zitat Miyazaki T, Fujimaki K, Shirasugi Y et al (2007) Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol 82:1106–1109PubMedCrossRef Miyazaki T, Fujimaki K, Shirasugi Y et al (2007) Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol 82:1106–1109PubMedCrossRef
35.
Zurück zum Zitat Bernatsky S, Clarke A, Suissa S (2008) Lung cancer after exposure to disease modifying anti-rheumatic drugs. Lung Cancer 59:266–269PubMedCrossRef Bernatsky S, Clarke A, Suissa S (2008) Lung cancer after exposure to disease modifying anti-rheumatic drugs. Lung Cancer 59:266–269PubMedCrossRef
36.
Zurück zum Zitat Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19, 562 patients during 89, 710 person-years of observation. Arthritis Rheum 56:1433–1439PubMedCrossRef Wolfe F, Michaud K (2007) The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19, 562 patients during 89, 710 person-years of observation. Arthritis Rheum 56:1433–1439PubMedCrossRef
Metadaten
Titel
Incidence of malignancy in Japanese patients with rheumatoid arthritis
verfasst von
Toru Yamada
Ayako Nakajima
Eisuke Inoue
Eiichi Tanaka
Atsuo Taniguchi
Shigeki Momohara
Hisashi Yamanaka
Publikationsdatum
01.11.2011
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 11/2011
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-010-1524-0

Weitere Artikel der Ausgabe 11/2011

Rheumatology International 11/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.